Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
present a poster entitled “Flex-201: A Multicenter, Randomized,
Blinded Study to Evaluate the Efficacy and Tolerability of
FLX-787 in MS” at the Americas Committee for Treatment and
Research in Multiple Sclerosis (ACTRIMS) 2017 Forum. The poster
is furnished herewith as Exhibit 99.1.
attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
|
Exhibit No.
|
Description
|
||
|
99.1
|
Flex Pharma, Inc. poster.
|
||
About Flex Pharma, Inc. (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs. Flex Pharma, Inc. (NASDAQ:FLKS) Recent Trading Information
Flex Pharma, Inc. (NASDAQ:FLKS) closed its last trading session 00.00 at 4.41 with 20,923 shares trading hands.
